Companies

Dr Reddy’s recalls 1,752 bottles of heartburn drug in the US

PTI New Delhi | Updated on May 10, 2020 Published on May 10, 2020

File photo   -  BusinessLine

Drug major Dr Reddy’s Laboratories is recalling 1,752 bottles of generic heartburn medicine in the US after the American health regulator found quality issues with the product.

As per the latest Enforcement Report by the the United States (US) Food and Drug Administration (USFDA), the Hyderabad-based drug firm is voluntarily recalling 1,752 bottles (1,000 count) of 40 mg Esomeprazole Magnesium delayed release capsules in the US.

The ongoing Class III recall is on account of “Discolouration” and because the product contains brown pellets, USFDA said.

As per the US health regulator, a class III recall is initiated in a situation “in which use of or exposure to a violative product is not likely to cause adverse health consequences“.

The recalled product lot has been manufactured at Dr Reddy’s Bachupally manufacturing facility in Telangana and is being recalled by the company’s US-based arm.

Esomeprazole Magnesium delayed release capsules are indicated to reduce the amount of acid in the stomach and other symptoms associated with GERD (gastroesophageal reflux disease).

In February last year, the company had announced recall of 20,78,490 bottles of Esomeprazole Magnesium delayed-release capsules in the US market.

Published on May 10, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.